9/8/22:
Selvaraju opined that AEterna should easily and quickly find a new partner to replace Novo and may even negotiate a better share of Macrilen Dx sales revenue. The analyst expects the product to gain traction in Europe, too, given, he wrote, it is safe, is as accurate as standard insulin tolerance testing (ITT), and unlike ITT, it can prevent adult growth hormone deficiency overdiagnosis.
In other macimorelin news, indicated Selvaraju, AEterna partnered with Consilient Health to commercialize the drug, under the name Ghryvelin, in Europe, where it was approved in 2019. Per the agreement between the two companies, AEterna is to receive 10–20% royalties on net sales.
"We remain optimistic on Ghryvelin adoption in Europe," Selvaraju wrote. "We believe Ghryvelin's oral convenience and ability to stimulate growth hormone within one hour are desirable attributes that should resonate with the European Union physician community."
US Co. To Regain All Rights to Its AGHD Diagnostic Test (streetwisereports.com)